This page shows the latest Zavicefta news and features for those working in and with pharma, biotech and healthcare.
It’s been sold in Europe by Pfizer as Zavicefta since 2016.
The antibiotic is sold in Europe by Pfizer under the Zavicefta brand name and got a green light from the EMA in 2016. ... Zavicefta is already approved in Europe for HABP/VABP. One of the key roles for the new product is in the treatment of infections
Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year. ... The availability of Zavicefta is a major step forward for
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
EMA approves combination drug for treatment of multidrug resistant infections. AstraZeneca's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been approved for marketing in the EU. ... The European Medicines Agency (EMA) cleared
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...